Objective:

To report on the management of a patient with severe PTSD and psychotic depression during pregnancy, focusing on the use of milnacipran and its clinical outcomes.

Key Findings:

• Milnacipran led to marked clinical improvement before pregnancy.
• Switching to sertraline and quetiapine resulted in a relapse of depressive symptoms and suicidal behavior.
• Resuming milnacipran after shared decision-making led to renewed improvement.
• No congenital anomalies or neonatal adaptation problems were observed at delivery.
• Pediatric developmental screenings at 3-year follow-up remained within expected limits.

Interpretation:

This case underscores the complexity of managing severe psychiatric conditions during pregnancy, particularly when evidence for medication safety is limited, highlighting the need for careful risk-benefit analysis.

Limitations:

• Limited data on milnacipran's safety during pregnancy may affect treatment decisions.
• As a single case study, findings may not be generalizable.
• Retrospective data collection could introduce biases.

Conclusion:

Balancing treatment efficacy and safety during pregnancy is challenging, particularly for medications with limited safety data like milnacipran, emphasizing the importance of shared decision-making.